Skip to main content
SpringerLink
Log in
Book cover

Handbook on the Neuropsychology of Aging and Dementia pp 335–353Cite as

After the Diagnosis of Dementia: Considerations in Disease Management

  • Chapter
  • First Online:

Part of the book series: Clinical Handbooks in Neuropsychology ((CHNEURO))

Abstract

Once diagnosed with Alzheimer’s disease or related disorders, patients and caregivers must integrate treatment and management plans. While there are no cures for these disorders, there are opportunities to optimize function and quality of life. There are pharmacological treatments available for dementia as well as for the behavioral and psychiatric symptoms that often accompany these diagnoses. Persistence can insure that drug treatments provide optimal benefit. Also nonpharmacological interventions including environmental modifications can be helpful, particularly for the behavioral problems. Supervision to insure adequate medical care, maximize independence and social interaction, and preserve patient dignity will require ongoing review of the patient’s changing condition. A comprehensive approach to management will also consider legal and financial needs, support for the caregiver, and the possibility of research participation. Clinicians can introduce the possibility of research for the hope it offers to their patients and to the generations to come.

This chapter is reprinted unchanged from the first edition of this handbook.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Burgener SC, Berger B. Measuring perceived stigma in persons with progressive neurological disease: Alzheimer’s dementia and Parkinson’s disease. Dementia. 2008;7:31–53.

    Article  Google Scholar 

  2. Kraemer HC, Tinklenberg J, Yesavage JA. ‘How far’ vs ‘how fast’ in Alzheimer disease: the question revisited. Arch Neurol. 1994;51:275–9.

    Article  Google Scholar 

  3. Behuniak SM. The living dead? The construction of people with Alzheimer’s disease as zombies. Ageing Soc. 2011;31:70–92.

    Article  Google Scholar 

  4. Kaye ED, Petrovic-Poljak A, Verhoeff NPLG, Freedman M. Frontotemporal dementia and pharmacologic interventions. J Neuropsychiatry Clin Neurosci. 2010;22:19–29.

    Article  Google Scholar 

  5. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.

    Article  Google Scholar 

  6. Riordan KC, Hoffman Snyder CR, Wellik KE, Caselli RJ, Wingerchuk DM, Demaerschalk BM. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic. Neurologist. 2011;17:121–3.

    Article  Google Scholar 

  7. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s disease cooperative study. N Engl J Med. 1997;336:1216–22.

    Article  Google Scholar 

  8. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379–88.

    Article  Google Scholar 

  9. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. J Am Med Assoc. 2008;300:1774–83.

    Article  Google Scholar 

  10. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. J Am Med Assoc. 2010;304:1903–11.

    Article  Google Scholar 

  11. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009;10:31.

    Article  Google Scholar 

  12. Roman MW. Axona (Accera, Inc): a new medical food therapy for persons with Alzheimer’s disease. Issues Ment Health Nurs. 2010;31:435–6.

    Article  Google Scholar 

  13. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, et al. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement. 2010;6(1):10.

    Article  Google Scholar 

  14. Hulme C, Wright J, Crocker T, Oluboyede Y, House A. Non-pharmacological approaches for dementia that informal carers might try or access: a systematic review. Int J Geriatr Psychiatry. 2009;25:756–63.

    Article  Google Scholar 

  15. Desai AK, Grossberg GT. Diagnosis and treatment of Alzheimer’s disease. Neurologic disorders update: current thinking and practices. Neurology. 2005;64:34–9.

    Article  Google Scholar 

  16. Swanson KA, Carnahan RM. Dementia and comorbidities: an overview of diagnosis and management. J Pharm Pract. 2007;20(4):296–317.

    Article  Google Scholar 

  17. Martin BK, Frangakis CE, Rosenberg PB, Mintzer JE, Katz IR, Porsteinsson AP, et al. Design of depression in Alzheimer’s disease study-2. Am J Geriatr Psychiatry. 2006;14:920–30.

    Article  Google Scholar 

  18. Lyketsos CG, Steele C, Galik E, Rosenblatt A, Steinberg M, Warren A, et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry. 1999;156:66–71.

    Article  Google Scholar 

  19. Teri L. Behavior and caregiver burden: behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord. 1997;11:35–8.

    Google Scholar 

  20. Olin JT, Katz IS, Meyer BS, Schneider LS, Lebowitz BD. Provisional diagnostic criteria for depression of Alzheimer’s disease: rationale and background. Am J Geriatr Psychiatry. 2002;10:129–41.

    Article  Google Scholar 

  21. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153:234–7.

    Google Scholar 

  22. Herrmann N. Use of SSRIs in the elderly: obvious benefits but unappreciated risks. Can J Clin Pharmacol. 2000;7:91–5.

    Google Scholar 

  23. Teri L, Gallagher-Thompson D. Cognitive-behavioral interventions for treatment of depression in Alzheimer’s patients. Gerontologist. 1991;31:413–6.

    Article  Google Scholar 

  24. Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. J Am Med Assoc. 2003;290:2015–22.

    Article  Google Scholar 

  25. Zec RF, Burkett NR. Non-pharmacological and pharmacological treatment of the cognitive and behavioral symptoms of Alzheimer disease. NeuroRehabilitation. 2008;23:425–38.

    Article  Google Scholar 

  26. Teri L, Logsdon RG. Identifying pleasant activities for Alzheimer’s disease patients: the pleasant events schedule-AD. Gerontologist. 1991;31:124–7.

    Article  Google Scholar 

  27. Weiner MF, Teri L. Psychological and behavioral management. In: Weiner MF, Lipton AM, editors. The dementias: diagnosis, treatment and research. Washington, D.C: American Psychiatric Publishing, Inc; 2003. p. 181–218.

    Chapter  Google Scholar 

  28. Chemerinski E, Petracca G, Manes F, Leiguarda R, Starkstein SE. Prevalence and correlates of anxiety in Alzheimer’s disease. Depress Anxiety. 1998;7:166–70.

    Article  Google Scholar 

  29. Luxenberg JS. Clinical issues in the behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry. 2000;15:5–8.

    Article  Google Scholar 

  30. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and cognitive impairment: results from the cardiovascular health study. J Am Med Assoc. 2002;288:1475–83.

    Article  Google Scholar 

  31. Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. 2004;3:485–93.

    Article  Google Scholar 

  32. Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf. 2011;10:35–43.

    Article  Google Scholar 

  33. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4–15.

    Article  Google Scholar 

  34. Delirium GOC. Am Fam Physician. 2003;67:1027–34.

    Google Scholar 

  35. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean R, Beers MH. Updating the beers criteria for potentially inappropriate medication use in older adults: results of a U.S. panel of experts. Arch Intern Med. 2003;163:2716–24.

    Article  Google Scholar 

  36. Gilley DW, Wilson RS, Beckett LA, Evans DA. Psychotic symptoms and physically aggressive behavior in Alzheimer’s disease. J Am Geriatr Soc. 1997;45:1074–9.

    Article  Google Scholar 

  37. Tariot PN, Blazina L. The psychopathology of dementia. In: Morris JC, editor. Handbook of dementing illnesses, neurological disease and therapy. New York: Marcel Dekker, Inc; 1994. p. 461–76.

    Google Scholar 

  38. Whitehouse PJ, Patterson MB, Strauss ME, Geldmacher DS, Mack JL, Gilmore GC, et al. Hallucinations Int Psychogeriatr. 1996;8:387–92.

    Article  Google Scholar 

  39. Schneider LS, Pierre N, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, et al. Effectiveness of atypical antipsychotics in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–38.

    Article  Google Scholar 

  40. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. J Am Med Assoc. 2005;293:596–608.

    Article  Google Scholar 

  41. Nagaratnam N, Lewis-Jones M, Scott D, Palazzi L. Behavioral and psychiatric manifestations in dementia patients in a community: caregiver burden and outcome. Alzheimer Dis Assoc Disord. 1998;12:330–4.

    Article  Google Scholar 

  42. Cohen-Mansfield J, Mintzer JE. Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord. 2005;19:37–40.

    Article  Google Scholar 

  43. Mann AH, Graham N, Ashby D. Psychiatric illness in residential homes for the elderly: a survey in one London borough. Age Aging. 1984;13(5):257–65.

    Article  Google Scholar 

  44. Buchanan JA, Christenson AM, Ostrom C, Hofman N. Non-pharmacological interventions for aggression in persons with dementia: a review of the literature. Behav Analyst Today. 2007;8:413–25.

    Article  Google Scholar 

  45. Inouye SK. Chapter 26. Delirium and other mental status problems in the older patient. In: Goldman L, Ausiello D, editors. Cecil medicine. 23rd ed. Philadelphia: Saunders Elsevier; 2007.

    Google Scholar 

  46. Francis J. Delusions, delirium, and cognitive impairment: the challenge of clinical heterogeneity. J Am Geriatr Soc. 1992;40:844–9.

    Article  Google Scholar 

  47. Fick DM, Agostini JV, Inouye SK. Delirium superimposed on dementia: a systematic review. J Am Geriatr Soc. 2002;50:1723–32.

    Article  Google Scholar 

  48. Flaherty JH. The evaluation and management of delirium among older persons. Med Clin North Am. 2011;95:555–77.

    Article  Google Scholar 

  49. Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. A comparison of psychiatric symptoms in vascular dementia and Alzheimer’s disease. Am J Psychiatry. 1993;156:1806–12.

    Google Scholar 

  50. Aharon-Peretz J, Masiah A, Pillar T, Epstein R, Tzischinsky OP, Lavie P. Sleep-wake cycles in multi-infarct dementia and dementia of the Alzheimer’s type. Neurology. 1991;41:1616–9.

    Article  Google Scholar 

  51. Ala TA, Yang KH, Sung JH, Frey WH II. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer’s disease at presentation a clinicopathological study. J Neurol Neurosurg Psychiatry. 1997;62:16–21.

    Article  Google Scholar 

  52. Boeve BF, Silber MH, Ferman TJ, Kokmen E, Smith GE, Ivnik RJ, et al. REM sleep behavior disorder and degenerative dementia—an association likely reflecting Lewy body disease. Neurology. 1998;51:363–70.

    Article  Google Scholar 

  53. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J. 1992;305:673–8.

    Article  Google Scholar 

  54. Lindau M, Almkvist O, Johansson SE, Wahlund LO. Cognitive and behavioral differentiation of frontal lobe degeneration of the non-Alzheimer’s type and Alzheimer’s disease. Dement Geriatr Cogn Disord. 1997;9:205–13.

    Article  Google Scholar 

  55. Mendez MF, Perryman KM, Miller BL, Cummings JL. Behavioral differences between frontotemporal dementia and Alzheimer’s disease: a comparison on the BEHAVE-AD rating scale. Int Psychogeriatr. 1998;10:155–62.

    Article  Google Scholar 

  56. Whitehouse P, Frisoni G, Post S. Breaking the diagnosis of dementia. Lancet Neurol. 2004;3:124–8.

    Article  Google Scholar 

  57. Gauthier S. Advances in the pharmacotherapy of Alzheimer’s disease. Can Med Assoc J. 2002;166:616–23.

    Google Scholar 

  58. Logsdon RG, Pike KC, McCurry SM, Hunter P, Maher J, Snyder L, et al. Early-stage memory loss support groups: outcomes from a randomized controlled clinical trial. J Gerontol B Psychol Sci Soc Sci. 2010;65:691–7.

    Article  Google Scholar 

  59. Goldsilver PM, Gruneir MRB. Early stage dementia group: an innovative model of support for individuals in the early stages of dementia. Am J Alzheimers Dis Other Demen. 2001;16:109–14.

    Article  Google Scholar 

  60. Logsdon RG, McCurry SM, Teri L. Timelimited support groups for individuals with early stage dementia and their care partners: preliminary outcomes from a controlled clinical trial. Clin Gerontol. 2006;30:5–19.

    Article  Google Scholar 

  61. Zarit SH, Femia EE, Watson J, Rice-Oeschger L, Kakos B. Memory club: a group intervention for people with early-stage dementia and their care partners. Gerontologist. 2004;44:262–9.

    Article  Google Scholar 

  62. Gräßel E, Trilling A, Donath C, Luttenberger K. Support groups for dementia caregivers—predictors for utilisation and expected quality from a family caregiver’s point of view: a questionnaire survey PART I. BMC Health Serv Res. 2010;10:219–26.

    Article  Google Scholar 

  63. Kurz A, Hallauer J, Jansen S, Diehl J. Efficacy of caregiver support groups for dementia. Nervenarzt. 2005;76:261–9.

    Article  Google Scholar 

  64. Thompson C, Spilsbury K. WITHDRAWN: support for carers of people with Alzheimer’s type dementia. Cochrane Database Syst Rev 2007;(2):CD000454.

    Google Scholar 

  65. Mittelman MS, Ferris SH, Shulman E, Steinberg G, Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease: a randomized controlled trial. J Am Med Assoc. 1996;276:1725–31.

    Article  Google Scholar 

  66. Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer’s disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010;6:202–11.

    Article  Google Scholar 

  67. Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al. Clinical core of the Alzheimer’s disease neuroimaging initiative: progress and plans. Alzheimers Dement. 2010;6:239–46.

    Article  Google Scholar 

  68. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:257–62.

    Article  Google Scholar 

  69. Pul R, Dodel R, Stangel M. Antibody-based therapy in Alzheimer’s disease. Expert Opin Biol Ther. 2011;11:343–57.

    Article  Google Scholar 

  70. National Institutes of Health. Studies find possible new genetic risk factors for Alzheimer’s disease [Press Release]. http://www.nia.nih.gov/newsroom/2011/04/studies-find-possible-new-genetic-risk-factors-alzheimers-disease. 2011.

Download references

Acknowledgments

This work was supported in part by the Alzheimer Disease Research Center at Mount Sinai funded by the following NIA grant: AG 005138.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA

    Steven Hoover & Mary Sano

  2. James J Peters Veterans Administration Medical Center, Bronx, NY, USA

    Mary Sano

Authors
  1. Steven Hoover
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Sano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary Sano .

Editor information

Editors and Affiliations

  1. Department of Neurology, Weill Cornell Medicine, New York, NY, USA

    Lisa D. Ravdin

  2. Department of Neurology, University of Miami, Miami, FL, USA

    Heather L. Katzen

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hoover, S., Sano, M. (2019). After the Diagnosis of Dementia: Considerations in Disease Management. In: Ravdin, L.D., Katzen, H.L. (eds) Handbook on the Neuropsychology of Aging and Dementia. Clinical Handbooks in Neuropsychology. Springer, Cham. https://doi.org/10.1007/978-3-319-93497-6_22

Download citation

Publish with us

Policies and ethics

Search

Navigation